Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myrcludex B plus tenofovir vs tenofovir alone in chronic hepatitis D
2016-000395-13Phase 2Completed
- Sponsor
- Hepatera
- Start
- Feb 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bulevirtide in Chronic Viral Hepatitis B With Delta-Agent and Chronic Hepatitis B (CHB) (4 arms), sponsored by Hepatera. Primary endpoint: HDV RNA response at Week 24. Started Feb 2016; status: completed.
02
Drugs
bulevirtide
03
Conditions
Chronic Viral Hepatitis B With Delta-AgentChronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2016-000395-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000395-13.